Gugu Maphalala1, Nomcebo Phungwayo2, Gilbert Masona3, Njabulo Lukhele4, Getahun Tsegaye3, Nomsa Dube5, Dlamini Sindisiwe6, Lonkululeko Khumalo7, Fussum Daniel8, Reggis Katsande9, Jacqueline E Tate8, Jason M Mwenda10, Goitom Weldegebriel9. 1. National Reference Laboratory, Surveillance Laboratory, Swaziland. Electronic address: gpmaph@gmail.com. 2. National Reference Laboratory, Surveillance Laboratory, Swaziland. 3. Raleigh Fitkin Memorable Hospital, Swaziland. 4. Mbabane Government Hospital, Swaziland. 5. Ministry of Health, Expanded Programme for Immunization, Swaziland. 6. Swaziland Health Laboratory Services, Swaziland. 7. World Health Organization Country Office, Swaziland. 8. Centres for Disease Control and Prevention, USA. 9. World Health Organization IST ESA, Harare, Zimbabwe. 10. World Health Organization Regional Office for Africa, Brazzaville, Congo.
Abstract
BACKGROUND: Swaziland introduced rotavirus vaccine in the National Immunization Program, in May 2015, with the objective of reducing the burden of rotavirus diarrheal disease. We monitored the early impact of the vaccine in reducing rotavirus diarrhea. METHODS: We conducted sentinel rotavirus surveillance from January 2013 to December 2016 in children under five years of age admitted due to diarrhea attending Mbabane Government Referral Hospital in the Hhohho Region and Raleigh Fitkin Memorial Hospital in the Manzini Region. All cases had stool samples collected and tested for rotavirus antigen by enzyme immunoassay. RESULTS: Between 2013 and 2016, 596 samples were collected and tested. Rotavirus positivity reduced from average of 50.8% (172/338) (in 2013-2014 (pre vaccine period)) to 29% (24/82) in 2016, post-vaccine introduction. The median age of children with rotavirus infection increased from average of 10months in 2013-2014 to 13.7months in 2016. The peak season for all-cause diarrhea and rotavirus-specific hospitalizations among children under five years of age was June-August in all years with a blunting of the peak season in 2016. Rotavirus positivity among children 0-11months reduced from an average of 49% in 2013-2014 (116/236) to 33% (15/45) in 2016, a 33% reduction following rotavirus vaccine introduction. CONCLUSION: There has been a rapid reduction of all-cause diarrhea and rotavirus hospitalizations in Swaziland, particularly in young children and during the rotavirus season, after the introduction rotavirus vaccine. Continued surveillance is needed to monitor the long-term impact of rotavirus vaccine introduction.
BACKGROUND: Swaziland introduced rotavirus vaccine in the National Immunization Program, in May 2015, with the objective of reducing the burden of rotavirus diarrheal disease. We monitored the early impact of the vaccine in reducing rotavirus diarrhea. METHODS: We conducted sentinel rotavirus surveillance from January 2013 to December 2016 in children under five years of age admitted due to diarrhea attending Mbabane Government Referral Hospital in the Hhohho Region and Raleigh Fitkin Memorial Hospital in the Manzini Region. All cases had stool samples collected and tested for rotavirus antigen by enzyme immunoassay. RESULTS: Between 2013 and 2016, 596 samples were collected and tested. Rotavirus positivity reduced from average of 50.8% (172/338) (in 2013-2014 (pre vaccine period)) to 29% (24/82) in 2016, post-vaccine introduction. The median age of children with rotavirus infection increased from average of 10months in 2013-2014 to 13.7months in 2016. The peak season for all-cause diarrhea and rotavirus-specific hospitalizations among children under five years of age was June-August in all years with a blunting of the peak season in 2016. Rotavirus positivity among children 0-11months reduced from an average of 49% in 2013-2014 (116/236) to 33% (15/45) in 2016, a 33% reduction following rotavirus vaccine introduction. CONCLUSION: There has been a rapid reduction of all-cause diarrhea and rotavirus hospitalizations in Swaziland, particularly in young children and during the rotavirus season, after the introduction rotavirus vaccine. Continued surveillance is needed to monitor the long-term impact of rotavirus vaccine introduction.
Authors: Negar Aliabadi; Sébastien Antoni; Jason M Mwenda; Goitom Weldegebriel; Joseph N M Biey; Dah Cheikh; Kamal Fahmy; Nadia Teleb; Hossam Abdelrahman Ashmony; Hinda Ahmed; Danni S Daniels; Dovile Videbaek; Annemarie Wasley; Simarjit Singh; Lucia Helena de Oliveira; Gloria Rey-Benito; N Jennifer Sanwogou; Pushpa Ranjan Wijesinghe; Jayantha B L Liyanage; Batmunkh Nyambat; Varja Grabovac; James D Heffelfinger; Kimberley Fox; Fem Julia Paladin; Tomoka Nakamura; Mary Agócs; Jillian Murray; Thomas Cherian; Catherine Yen; Umesh D Parashar; Fatima Serhan; Jacqueline E Tate; Adam L Cohen Journal: Lancet Glob Health Date: 2019-07 Impact factor: 26.763
Authors: Lauren M Schwartz; K Zaman; Md Yunus; Ahasan-Ul H Basunia; Abu Syed Golam Faruque; Tahmeed Ahmed; Mustafizur Rahman; Jonathan D Sugimoto; M Elizabeth Halloran; Ali Rowhani-Rahbar; Kathleen M Neuzil; John C Victor Journal: Clin Infect Dis Date: 2019-11-27 Impact factor: 9.079